Synne Jenum

Researcher

Department of Clinical Science

E-mailS.Jenum@uib.no
Visitor Address
Haukeland universitetssykehus, Laboratoriebygget

5009 Bergen
Postal Address
Postboks 7804

5020 Bergen

Publications

Academic article

Show author(s) (2024). Whole blood RNA signatures in tuberculosis patients receiving H56:IC31 vaccine as adjunctive therapy. Frontiers in Immunology.

Show author(s) (2023). The diagnostic utility of microscopic quality assessment of sputum samples in the era of rapid syndromic PCR testing. Microbiology spectrum.
Show author(s) (2023). The Cyclooxygenase 2 Inhibitor Etoricoxib as Adjunctive Therapy in Tuberculosis Impairs Macrophage Control of Mycobacterial Growth. Journal of Infectious Diseases. 888-897.
Show author(s) (2023). Host blood-based biosignatures for subclinical TB and incipient TB: A prospective study of adult TB household contacts in Southern India. Frontiers in Immunology. 17 pages.
Show author(s) (2023). Gut microbiota composition during hospitalization is associated with 60-day mortality after severe COVID-19. Critical Care.

Show author(s) (2022). Use of an extended KDIGO definition to diagnose acute kidney injury in patients with COVID-19: A multinational study using the ISARIC–WHO clinical characterisation protocol. PLoS Medicine. 21 pages.
Show author(s) (2022). Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study. Critical Care. 16 pages.
Show author(s) (2022). Neurological manifestations of COVID-19 in adults and children. Brain. 14 pages.
Show author(s) (2022). Improving Assignments for Therapeutic and Prophylactic Treatment Within TB Households. A Potential for Immuno-Diagnosis? Frontiers in Immunology. 11 pages.
Show author(s) (2022). ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19. Scientific Data. 22 pages.
Show author(s) (2022). Host Transcriptional Signatures Predict Etiology in Community-Acquired Pneumonia: Potential Antibiotic Stewardship Tools. Biomarker Insights. 1-8.
Show author(s) (2022). Association of body mass index with COVID-19 related in-hospital death. Clinical Nutrition. 2924-2926.
Show author(s) (2022). An international observational study to assess the impact of the Omicron variant emergence on the clinical epidemiology of COVID-19 in hospitalised patients. eLIFE. 21 pages.

Show author(s) (2021). Ten months of temporal variation in the clinical journey of hospitalised patients with COVID-19: An observational cohort. eLIFE. 1-30.
Show author(s) (2021). Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients. Frontiers in Cellular and Infection Microbiology. 1-13.
Show author(s) (2021). Host blood RNA transcript and protein signatures for sputum-independent diagnostics of tuberculosis in adults. Frontiers in Immunology. 1-10.
Show author(s) (2021). En mann i 70-årene med pleuravæske, knesmerter og dysartri etter åpen hjertekirurgi. Tidsskrift for Den norske legeforening. 9 pages.
Show author(s) (2021). Critical COVID-19 is associated with distinct leukocyte phenotypes and transcriptome patterns. Journal of Internal Medicine. 1-16.
Show author(s) (2021). Clinical characteristics, risk factors and outcomes in patients with severe COVID-19 registered in the ISARIC WHO clinical characterisation protocol: a prospective, multinational, multicentre, observational study. European Respiratory Journal Open Research (ERJ Open Research). 18 pages.
Show author(s) (2021). COVID‐19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study. Infection. 889-905.
Show author(s) (2021). CCL1 and IL-2Ra differentiate Tuberculosis disease from latent infection Irrespective of HIV infection in low TB burden countries. Journal of Infection. 1-11.
Show author(s) (2021). A Plasma 5-Marker Host Biosignature Identifies Tuberculosis in High and Low Endemic Countries. Frontiers in Immunology. 1-13.
Show author(s) (2021). A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients. Nature Communications.
Show author(s) (2021). A 2-Dose AERAS-402 Regimen Boosts CD8<sup>+</sup> Polyfunctionality in HIV-Negative, BCG-Vaccinated Recipients. Frontiers in Immunology. 1-15.

Show author(s) (2020). Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients . Proceedings of the National Academy of Sciences of the United States of America. 25018-25025.
Show author(s) (2020). Monocytic myeloid-derived suppressor cells reflect tuberculosis severity and are influenced by cyclooxygenase-2 inhibitors. Journal of Leukocyte Biology.
Show author(s) (2020). Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19. Scientific Reports. 11 pages.
Show author(s) (2020). Identification of subclinical tuberculosis in household contacts using exposure scores and contact investigations. BMC Infectious Diseases. 1-11.
Show author(s) (2020). Elevated plasma sTIM-3 levels in patients with severe COVID-19. Journal of Allergy and Clinical Immunology. 92-98.
Show author(s) (2020). Elevated Levels of Anti-Inflammatory Eicosanoids and Monocyte Heterogeneity in Mycobacterium tuberculosis Infection and Disease. Frontiers in Immunology.
Show author(s) (2020). Combining host-derived biomarkers with patient characteristics improves signature performance in predicting tuberculosis treatment outcomes. Communications Biology. 1-10.

Show author(s) (2019). Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Mycobacterium tuberculosis infection in aerosol-challenged mice. Communications Biology. 1-10.

Show author(s) (2018). Incidence of tuberculosis and the influence of surveillance strategy on tuberculosis case-finding and all-cause mortality: A cluster randomised trial in Indian neonates vaccinated with BCG. BMJ Open Respiratory Research. 1-9.
Show author(s) (2018). Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: a prospective, multicentre, observational cohort study. Journal of Antimicrobial Chemotherapy. 2503-2509.

Show author(s) (2017). Novel transcriptional signatures for sputum-independent diagnostics of tuberculosis in children. Scientific Reports. 1-9.

Show author(s) (2016). BLR1 and FCGR1A transcripts in peripheral blood associate with the extent of intrathoracic tuberculosis in children and predict treatment outcome. Scientific Reports. 1-11.
Show author(s) (2016). Approaching a diagnostic point-of-care test for pediatric tuberculosis through evaluation of immune biomarkers across the clinical disease spectrum. Scientific Reports.
Show author(s) (2016). Added Value of IP-10 as a Read-Out of Mycobacterium tuberculosis - Specific Immunity in Young Children. The Pediatric Infectious Disease Journal.

Show author(s) (2014). The frequencies of IFNγ+IL2+TNFα+ PPD-specific CD4+CD45RO+ T-cells correlate with the magnitude of the QuantiFERON® gold in-tube response in a prospective study of healthy Indian adolescents. PLOS ONE.
Show author(s) (2014). TB Trials Study Group: Concordant or discordant results by the tuberculin skin test and the quantiFERON-TB test in children reflect immune biomarker profiles. Genes and Immunity. 265-274.
Show author(s) (2014). Influence of age and nutritional status on the performance of the tuberculin skin test and QuantiFERON®-TB Gold In-Tube in young children evaluated for tuberculosis in southern India. The Pediatric Infectious Disease Journal. e260-e269.
Show author(s) (2014). Effect of non-tuberculous mycobacteria on host biomarkers potentially relevant for tuberculosis management. PLoS Neglected Tropical Diseases.
Show author(s) (2014). Concordant or discordant results by the tuberculin skin test and the quantiFERON-TB test in children reflect immune biomarker profiles. Genes and Immunity. 265-274.

Show author(s) (2013). Identification of biomarkers for Mycobacterium tuberculosis infection and disease in BCG-vaccinated young children in Southern India. Genes and Immunity. 356-364.

Academic lecture

Show author(s) (2019). TBCOX2 study: Host-directed therapy in tuberculosis .

Show author(s) (2017). Host directed therapy, new treatment options for resistant tuberculosis .